Amino-terminal propeptides of type III procollagen in seminal fluid.

1984 ◽  
Vol 30 (3) ◽  
pp. 488-490 ◽  
Author(s):  
A M Gressner ◽  
H H Neu
1989 ◽  
Vol 9 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Kirsten D. Bentsen ◽  
Jens H. Henriksen ◽  
Steen Boesby ◽  
Kim Hørslev-Petersen ◽  
Ib Lorenzen

Burns ◽  
2002 ◽  
Vol 28 (8) ◽  
pp. 766-771 ◽  
Author(s):  
Dietmar Ulrich ◽  
Ernst-Magnus Noah ◽  
Elmar Reinhardt Burchardt ◽  
Derek Atkins ◽  
Norbert Pallua

Author(s):  
Cindy Soendersoe Knudsen ◽  
Lene Heickendorff ◽  
Ebba Nexo

AbstractRecently, measurement of amino terminal propeptide of type III procollagen (PIIINP) was introduced as a part of the hepatic cirrhotic marker enhanced liver fibrosis™ test on the automated ADVIA CentaurWe analyzed four control samples 20 times over a period of 5 days. Centaur PIIINP assay measurements were compared with the widely used UniQ PIIINP RIA assay (Orion Diagnostica, Espoo, Finland) using 55 patient samples (range=3.7–43.3 µg/L). Furthermore, we established a reference interval based on samples from 287 blood donors.In the concentration range 2.5–11.9 µg/L, the total imprecision was below 8%. Comparison with the UniQ PIIINP RIA assay yielded: Centaur PIIINP µg/L=1.9×(UniQ PIIINP RIA)+0.6 µg/L, rWe conclude that the Centaur PIIINP assay is suitable for routine use with our newly defined reference interval. The results obtained by Centaur correlates well with those obtained by the previously employed RIA, though the absolute values are higher.


1976 ◽  
Vol 70 (1) ◽  
pp. 205-216 ◽  
Author(s):  
Hans NOWACK ◽  
Bjorn R. OLSEN ◽  
Rupert TIMPL

1988 ◽  
Vol 34 (4) ◽  
pp. 715-718 ◽  
Author(s):  
J Risteli ◽  
S Niemi ◽  
P Trivedi ◽  
O Mäentausta ◽  
A P Mowat ◽  
...  

Abstract This is an equilibrium-type radioimmunoassay for the amino-terminal propeptide of type III procollagen (PIIINP), which overcomes the problem of nonparallelism between the standard and human serum samples encountered with earlier assays. Proper selection of antiserum and reaction conditions diminishes interference from degradation products of the propeptide in serum. Because a rapid solid-phase-bound second-antibody step is included, the assay takes only 3 h. The intra-assay and the interassay CVs are both about 5%. In infants and children the concentration of PIIINP in serum closely parallels the growth-velocity curve. For 88 presumably healthy adults, the PIIINP concentration was 1.7-4.2 micrograms/L, about a third that measured with the previously available commercial assay. This is because of lack of inhibition by small Col 1 domain-related degradation products.


Sign in / Sign up

Export Citation Format

Share Document